

Special Issue

Novel Therapeutic Approaches in Urothelial Carcinoma

Message from the Guest Editors

Recently, diagnostic and therapeutic advances have led to lower mortality rates for urothelial carcinoma (UC) patients. The standard of care for advanced UC remains platinum-based combination chemotherapy. However, the therapeutic landscape has been expanded with the Food and Drug Administration's approval of erdafitinib for tumors with a mutation or fusion, which activates fibroblast growth factor receptor (FGFR) 2/FGFR3.

Enfortumab vedotin and sacituzumab govitecan are indicated after progression to platinum-based chemotherapy and programmed cell death inhibitor 1/ligand 1. The increasing number of long-term responders to systemic treatments requires early identification and appropriate management of toxicities.

The next step is the analysis of somatic and germline genomics, aimed at the development of therapies directed at tumor-specific, druggable genetic targets. Identification of specific biomarkers is crucial for developing therapeutic strategies for UC patients. We invite you to submit papers:

- Genomic and molecular characterization;
- Identification of prognostic and predictive biomarkers;
- Therapeutic perspectives;
- Management of emerging therapies.

Guest Editors

Dr. Mimma Rizzo

Division of Medical Oncology, Azienda Ospedaliero Universitaria
Consortiale Policlinico di Bari, Bari, Italy

Dr. Patrizia Giannatempo

Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto
Nazionale dei Tumori, Milan, Italy

Deadline for manuscript submissions

closed (30 March 2024)



Medicina

an Open Access Journal
Published by MDPI

Impact Factor 2.4
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/159701

Medicina
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicina@mdpi.com

[mdpi.com/journal/
medicina](https://mdpi.com/journal/medicina)





Medicina

an Open Access Journal
Published by MDPI

Impact Factor 2.4
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/
medicina](https://mdpi.com/journal/medicina)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius
Medical Academy, Lithuanian University of Health Sciences, Kaunas,
Lithuania

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)